DSGN Company Profile and Key Details

Q: Who are the executives of DSGN?

Ms. Dawn GiangiulioControllerDr. Elizabeth Gordon Ph.D.Senior Vice President of Regulatory AffairsDr. Jae B. Kim FACC, M.D.Chief Medical OfficerDr. Sean Jeffries Ph.D.Chief Operating OfficerDr. Aseem Z. Ansari Ph.D.Co-Founder & Scientific AdvisorMs. Julie D. Burgess CPAChief Accounting OfficerMr. Pratik Shah Ph.D.Co-Founder & Executive ChairpersonDr. João Siffert M.D.Pres, Chief Executive Officer & Director

NASDAQ : DSGN

Design Therapeutics

$10.30

-0.74-6.70%

At Close 4:00 PM

60.11

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Design Therapeutics, Inc. (DSGN) stock declined over -6.70%, trading at $10.30 on NASDAQ, down from the previous close of $11.04. The stock opened at $10.84, fluctuating between $10.25 and $10.92 in the recent session.

Stock Snapshot

11.04

Prev. Close

586.73M

Market Cap

10.25

Day Low

-8.66

P/E Ratio

-1.19

EPS (TTM)

-1.1

Cash Flow per Share

10.84

Open

56.96M

Number of Shares

10.92

Day High

58.14%

Free Float in %

5.09

Book Value

351K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 18, 2026	10.96	10.99	10.25	10.30	354.25K
Mar 17, 2026	10.98	11.09	10.32	11.04	393.74K
Mar 16, 2026	10.58	11.23	10.24	10.99	1.16M
Mar 13, 2026	10.15	10.35	9.87	10.12	337.81K
Mar 12, 2026	9.89	10.16	9.76	10.02	238.02K
Mar 11, 2026	9.99	10.71	9.91	10.01	155.23K
Mar 10, 2026	10.54	10.83	9.69	9.99	225.42K
Mar 09, 2026	9.93	10.43	9.93	10.37	163.25K
Mar 06, 2026	9.86	10.15	9.85	10.05	165.48K
Mar 03, 2026	9.98	10.43	9.86	10.00	210.36K
Mar 02, 2026	10.19	10.47	9.88	10.23	150.02K
Feb 27, 2026	10.53	10.73	10.39	10.44	103.21K
Feb 26, 2026	11.00	11.00	10.41	10.68	129.99K
Feb 25, 2026	10.65	11.14	10.51	10.97	317.53K
Feb 24, 2026	10.38	10.71	10.31	10.60	180.48K
Feb 23, 2026	10.12	10.47	10.01	10.35	118.06K
Feb 20, 2026	10.17	10.44	9.88	10.11	170.76K
Feb 19, 2026	9.98	10.33	9.70	10.28	450.35K
Feb 18, 2026	10.14	10.40	10.00	10.03	144.76K
Feb 17, 2026	10.08	10.25	9.91	10.12	144.54K

Contact Details

Carlsbad, CA 92011

United States

https://www.designtx.com 858 293 4900

About Company

Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Stock Peers

REGN

-14.93-1.97%

Regeneron Pharmaceuticals, Inc.$744.12 ARGX

-21.26-3.01%

argenx SE$684.77 UTHR

-9.67-1.79%

United Therapeutics Corporation$530.35 VRTX

-10.9-2.36%

Vertex Pharmaceuticals Incorporated$451.59 MDGL

-1.18-0.27%

Madrigal Pharmaceuticals, Inc.$442.00 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-5.62-1.75%

Alnylam Pharmaceuticals, Inc.$314.80 PRAX

-14.59-4.81%

Praxis Precision Medicines, Inc.$288.79 KRYS

-5.5-2.15%

Krystal Biotech, Inc.$250.83 SGEN

-0.16-0.07%

Seagen Inc.$228.74

Company Overview

Design Therapeutics, Inc. (NASDAQ:DSGN) closed at $10.30 USD, losing -$0.74 (-6.70%) from the previous close of $11.04. The stock is currently mid-range between its 52-week high and low $2.60 and $11.23. With a market capitalization of about $586.73 million, Design Therapeutics, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~1.63). Key stats such as the average daily volume over the past year has been around 307.09 thousand shares, in line with its 52-week average. Headquartered in Carlsbad, CA, Design Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Pratik Shah, the company employs approximately 56 people and listed since March 29, 2021. Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions.

Technical Performance

DSGN has shown sold momentum, gaining 3.62% over the past week and 64.63% over the past quarter, though year-to-date performance is up 0.75%. Short-term trend indicators are bearishly aligned (SMA20 3.68%, SMA50 8.24%, SMA200 60.65%). The stock’s 14-day RSI is 57.83 (neutral), while the ATR of 0.58 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -4.13% below its high and over 310.77% above its low. Average 10-day trading volume of 379.07 thousand shares is slightly above the 3-month average of 305.66 thousand, indicating heightened recent market interest.

Valuation Metrics

Design Therapeutics, Inc. trades at a P/E ratio of -8.46, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.78 suggesting the stock is closer to book value. The P/FCF stands at -10.76, also below market averages.

Dividend & Fair Value

Design Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.28. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Design Therapeutics, Inc. generated EPS of -$1.19 over the past year. Five-year average earnings growth is -88.52%. Wall Street analysts project EPS growth of -18.76% annually over the next five years. The latest quarter delivered EPS of -$0.30. The next quarter is forecast at -$0.35. Next year's EPS is expected at -$7.92. Analyst sentiment is bullish. Analyst rating data shows there are 4 Strong Buy ratings, 1 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $18.00 to $6.00. The high target offers 74.76% upside. The low target suggests -41.75% downside. The mean target is $13.33. This offers 29.42% upside. Design Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by -11.76%. The prior quarter beat by 6.25%. Over the last six quarters, Apple has recorded several small beats. These include -16.0% in August 05, 2024.

Shareholding & Insider Activity

Design Therapeutics, Inc. has 56.95 million shares outstanding. The public float is 23.34 million shares, elevated short interest at 9.34% of float. This equals 3.52 million shares. The short ratio is 22.33 days. Institutional investors hold 98.45% of the float. Insiders own 35.98%. SR One Capital Fund I Aggregator LP holds 6.53 million shares, George Simeon has 6.53 million shares and Cormorant Asset Management, LP has 5.11 million shares.

Financial & Profitability Overview

Over the trailing twelve months, Design Therapeutics has not generated any revenue. Returns are negative, with ROA at -23.08% and ROE at -24.08%.
On valuation metrics, Design Therapeutics trades at a P/E of -8.46, P/S of 0.00 and P/B of 2.78. The current ratio is 17.14 and quick ratio is 17.14. Debt-to-equity is 0.00, supported by a cash flow-to-debt ratio of -84.28.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Design Therapeutics posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Operating income was - $78.19M (margin 0.0%). Net income was- $66.86M (EPS - $0.00).
The company ended the quarter with $281.80M in cash and short-term investments, a total debt of $2.33M, and net debt of - $18.87M. Total assets were $289.64M, with equity of $277.69M. Financials further reflected weakness, with operating cash flow of - $58.56M, free cash flow of - $58.82M, and capital expenditures of - $256.00K.

Price Forecast & Outlook

Our AI price prediction model suggests that Design Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.76%, with price expected at $10.79 by March 31, 2026, within a range of $10.51 to $11.04 3-Month Outlook: Projected fall of -33.01%, reaching $6.90 by June 15, 2026, with a range of $6.56 to $7.28. 1-Year Outlook: Projected gain of 266.6%, with price at $37.76 by March 17, 2027, within a range of $39.67 to $40.26.

Key Takeaways

Design Therapeutics, Inc. (NASDAQ:DSGN) shares are flat 0.75% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Design Therapeutics, Inc. trading at a premium to the broader market with a P/E of -8.46. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $17.00, suggesting 65.05% upside. Our AI forecast model points to short-term strength (4.76% over two weeks), a medium-term fall (-33.01% over three months), and a longer-term gain (266.6% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Design Therapeutics, Inc. (DSGN) stock price?

Design Therapeutics, Inc. (NASDAQ: DSGN) stock price is $10.30 in the last trading session. During the trading session, DSGN stock reached the peak price of $10.92 while $10.25 was the lowest point it dropped to. The percentage change in DSGN stock occurred in the recent session was -6.7% while the dollar amount for the price change in DSGN stock was - $0.74.

DSGN's industry and sector of operation?

The NASDAQ listed DSGN is part of Biotechnology industry that operates in the broader Healthcare sector. Design Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of DSGN?

Ms. Dawn Giangiulio
Controller
Dr. Elizabeth Gordon Ph.D.
Senior Vice President of Regulatory Affairs
Dr. Jae B. Kim FACC, M.D.
Chief Medical Officer
Dr. Sean Jeffries Ph.D.
Chief Operating Officer
Dr. Aseem Z. Ansari Ph.D.
Co-Founder & Scientific Advisor
Ms. Julie D. Burgess CPA
Chief Accounting Officer
Mr. Pratik Shah Ph.D.
Co-Founder & Executive Chairperson
Dr. João Siffert M.D.
Pres, Chief Executive Officer & Director

How DSGN did perform over past 52-week?

DSGN's closing price is 296.15% higher than its 52-week low of $2.60 where as its distance from 52-week high of $11.23 is -8.28%.

How many employees does DSGN have?

Number of DSGN employees currently stands at 56.

Link for DSGN official website?

Official Website of DSGN is: https://www.designtx.com

How do I contact DSGN?

DSGN could be contacted at phone 858 293 4900 and can also be accessed through its website. DSGN operates from 6005 Hidden Valley Road, Carlsbad, CA 92011, United States.

How many shares of DSGN are traded daily?

DSGN stock volume for the day was 351K shares. The average number of DSGN shares traded daily for last 3 months was 307.09K.

What is the market cap of DSGN currently?

The market value of DSGN currently stands at $586.73M with its latest stock price at $10.30 and 56.96M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	56
Beta	1.63
Sales or Revenue	$0.00
5Y Sales Change%	-1%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

DSGN Company Profile and Key Details

Design Therapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways